Genelux Co. (NASDAQ:GNLX – Get Free Report) was down 1.3% during trading on Friday . The company traded as low as $3.76 and last traded at $3.93. Approximately 93,061 shares traded hands during mid-day trading, a decline of 53% from the average daily volume of 199,940 shares. The stock had previously closed at $3.98.
Genelux Stock Down 1.3 %
The firm has a market capitalization of $135.73 million, a price-to-earnings ratio of -4.14 and a beta of -1.41. The firm’s 50 day moving average is $3.97 and its 200 day moving average is $3.07.
Institutional Investors Weigh In On Genelux
Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in Genelux during the 4th quarter worth about $25,000. Apollon Wealth Management LLC boosted its holdings in shares of Genelux by 20.4% in the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after buying an additional 2,857 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Genelux in the fourth quarter worth approximately $41,000. Brown Brothers Harriman & Co. raised its holdings in shares of Genelux by 76.2% during the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock valued at $50,000 after acquiring an additional 9,114 shares during the period. Finally, D.A. Davidson & CO. acquired a new stake in shares of Genelux during the fourth quarter valued at approximately $51,000. Institutional investors and hedge funds own 37.33% of the company’s stock.
Genelux Company Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Featured Articles
- Five stocks we like better than Genelux
- Most active stocks: Dollar volume vs share volume
- FedEx Delivers Another Crushing Blow to Its Stock Price
- Retail Stocks Investing, Explained
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- With Risk Tolerance, One Size Does Not Fit All
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
